Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 100 Campus Drive, Suite 102 FLORHAM PARK NJ 07932 |
Tel: | N/A |
Website: | https://www.phathompharma.com |
IR: | See website |
Key People | ||
Michael F. Cola Independent Chairman of the Board | Terrie J. Curran President, Chief Executive Officer, Director | Azmi Nabulsi Co-Founder, Chief Operating Officer | Molly Henderson Chief Financial Officer and Business Officer |
Business Overview |
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company's pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen. |
Financial Overview |
For the fiscal year ended 31 December 2023, Phathom Pharmaceuticals Inc revenues increased from $0K to $682K. Net loss increased 2% to $201.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest expense increase of 54% to $42M (expense), Stock-based Compensation in SGA increase of 76% to $32.7M (expense). |
Employees: | 452 as of Feb 29, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $595.95M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.68M as of Dec 31, 2023 |
EBITDA (TTM): | -$166.72M as of Dec 31, 2023 |
Net annual income (TTM): | -$201.59M as of Dec 31, 2023 |
Free cash flow (TTM): | -$139.21M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $63.38M as of Dec 31, 2023 |
Shares outstanding: | 58,524,101 as of Mar 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |